APAC Pharmacogenetics Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2029

Asia-Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing, and Chromosomal Array-Based Tests), Patient Type (Children’s, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, Software & Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution Hospital Pharmacy, and Others), Countries (China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Vietnam, Philippines, Indonesia, and Rest of the Asia-Pacific) - Industry Trends and Forecast to 2029

Market Definition
Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.
Pharmacogenetics testing studies the interaction between the drug and the gene response of a person and searches for the gene variation, which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individuals genes and provided valuable insights which subsequently be used to develop customized or personalized medication.

Market Segmentation
The Asia-Pacific pharmacogenetics testing in psychiatry/depression market is categorized into seven notable segments, which are the type, test type, product type, gene type, patient type, end user, and distribution channel.

• On the basis of type, the pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders

• On the basis of test type, the pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests

• On the basis of patient type, the pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics

• On the basis of product type, the pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services

•On the basis of gene type, the pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others

•On the basis of end user, the pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others

•On the basis of distribution channel, the pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacy, and others

Market Players:
Some of the major players operating in the Asia-Pacific pharmacogenetics testing in psychiatry/depression market are:
• Genewiz (Part of Azenta Life Sciences)
• PacBio
• QIAGEN
• Thermo Fisher Scientific Inc.
• AB BIOTICS.S.A.
• Eurofins Scientific
• Illumina, Inc.
• STADAPHARM GmbH
• Genomind, Inc.
• myDNA Life Australia Pty Ltd.
• Sonic Healthcare Limited